KALA Latest News, Press Relases and Analysis

All

Press Releases

19 days ago - By: Benzinga - Mentions: MNOV INTS EDSA PHGE ...

12 Health Care Stocks Moving In Friday's After-Market Session

a month ago - By: Benzinga - Mentions: NBY XRTX REPL RAPT ...

12 Health Care Stocks Moving In Monday's Intraday Session

2 months ago - By: Stocktwits - Mentions: VTI VXF

Kala Bio Stock Just Plunged 92% Today – Here’s What Happened

2 months ago - By: KALA BIO, Inc.

KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

3 months ago - By: KALA BIO, Inc.

KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: KALA BIO, Inc.

KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: KALA BIO, Inc.

KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

3 months ago - By: KALA BIO, Inc.

KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

3 months ago - By: Zacks Investment Research

Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade

3 months ago - By: The Motley Fool

Kala Bio (KALA) Q2 Loss Widens 15%

3 months ago - By: KALA BIO, Inc.

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: KALA BIO, Inc.

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: KALA BIO, Inc.

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

4 months ago - By: KALA BIO, Inc.

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

4 months ago - By: KALA BIO, Inc.

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

4 months ago - By: KALA BIO, Inc.

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

5 months ago - By: KALA BIO, Inc.

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

6 months ago - By: KALA BIO, Inc.

KALA BIO to Present at Jefferies Global Healthcare Conference

6 months ago - By: KALA BIO, Inc.

KALA BIO to Present at Jefferies Global Healthcare Conference

6 months ago - By: KALA BIO, Inc.

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

6 months ago - By: KALA BIO, Inc.

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

8 months ago - By: KALA BIO, Inc.

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

8 months ago - By: KALA BIO, Inc.

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

9 months ago - By: KALA BIO, Inc.

KALA BIO INC (KALA) Stock News

KALA Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

Kala Bio Stock Just Plunged 92% Today – Here’s What Happened

KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference

KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference

KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade

Kala Bio (KALA) Q2 Loss Widens 15%

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

KALA BIO to Present at Jefferies Global Healthcare Conference

KALA BIO to Present at Jefferies Global Healthcare Conference

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference